Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Phase I Clinical Study of SHR-7782 Injection in the Treatment of Advanced Malignant Cancer

NCT07123129 is registered in ClinicalTrials.gov with Suzhou Suncadia Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT07123129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07123129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Phase I Clinical Study of SHR-7782 Injection in the Treatment of Advanced Malignant Cancer
Lead sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
August 28, 2025
Completion date
December 31, 2027
Enrollment
200 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancy